

Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device (IUD), Injectable Birth Control, Vaginal Rings, and Others), Hormone (Progestin-only Contraceptive, Combined Hormonal Contraceptive), Age Group (15-24 Years, 25-34 Years, 35-44 Years, Above 44 Years), End User (Hospitals and Clinics, Homecare, Ambulatory Surgical Centers, and Others), and Region 2024-2032

https://marketpublishers.com/r/H86C88FCD84BEN.html

Date: September 2024 Pages: 138 Price: US\$ 3,509.00 (Single User License) ID: H86C88FCD84BEN

# **Abstracts**

The global hormonal contraceptive market size reached US\$ 18.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 26.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is experiencing steady growth driven by global awareness of reproductive health and family planning, the rising empowerment of women, particularly in developing regions, and the growing acceptance and use of contraceptives across the globe.

Hormonal Contraceptive Market Analysis:

Major Market Drivers: The demand for hormonal contraceptives is driven by family planning requirements and acceptance across the globe. The various governments and non-governmental organizations that solely try to reduce the rate of unplanned pregnancies are leading to the growth of this market.

Key Market Trends: According to the hormonal contraceptive market forecast, the recent trend that will have a major impact on this market is the increasing consumption of long-acting reversible contraceptives including IUDs and



implants on account of being more effective and longer action period.

Geographical Trends: North America and Western Europe majorly lead in hormonal contraceptive usage due to high awareness levels, income, and healthcare facilities. On the contrary, Asia Pacific is anticipated to grow fastest due to urbanization, healthcare expenditure, and lifestyle factors.

Competitive Landscape: According to the hormonal contraceptive market research, the hormonal contraceptives market has several big pharmaceutical companies with extensive product portfolios and distribution networks. Both small and large companies are increasing their budgetary allocation to research and development (R&D) activities to develop new drugs with minimal side effects while maintaining consumer convenience.

Challenges and Opportunities: While the existence of cultural resistance and regulatory hurdles in various geographical areas constrain market growth, there remain multiple opportunities to invest in personalized contraceptive solutions and focus on unaddressed emerging markets with an increase in female employment.

Hormonal Contraceptive Market Trends:

Increasing global awareness and education on reproductive health

The extensive utilization of hormonal contraceptives on a global scale is largely dependent on increased awareness and education about reproductive health. Governments and relevant international organizations, such as the World Health Organization, continuously promote the concept and advantages of family planning through safe and effective contraceptive use. According to the World Health Organization, there were 1.9 billion women of reproductive age worldwide in 2021, 1.1 billion of whom need family planning. Of these, 874 million are using modern contraceptive methods, and there are 164 million women with an unmet need for contraception. Thus, this is significantly influencing the hormonal contraceptive market revenue. Specifically, extensive global campaigns target both women and men, informing them about their ability to control pregnancies and effective ways to reduce rapid population growth. Moreover, numerous educational programs targeting teens and young individuals have been rolled out to lay the groundwork for well-informed family planning the planning decisions later in life. These educational initiatives are only effective when



complemented by access to healthcare services and consultations that enable individuals to differentiate among various hormonal contraceptive methods. In this regard, comprehensive global educational and health programs are indispensable in ensuring these products are taken up in different regions.

Technological advancements and product innovation

The development of new and better hormonal contraceptive options that revolutionize the area also propels hormonal contraceptive market value. Recently, a novel ultra-lowdose preparation of 20 ?g EE and 3 mg DRSP has been marketed in a 24/4 regimen (Yaz; Bayer AG). The efficacy is similar to, if not better than, older COCs, and the bleeding pattern is acceptable. Additionally, drug delivery system development is resulting in more reliable items that are simpler to manage and produce fewer side effects. Extended-cycle pills and improvements to intrauterine devices, such as fewer health hazards and a longer period of utilization, respectively, all address the increasing need for consumer convenience and lifestyle compatibility. In addition, such advancements enhance the consumer experience and compliance, resulting in an expanded market since women are more likely to use and resume contraceptive use. In addition, innovations in contraceptive product technologies take advantage of consumers' acquired interest and adoption and market choice to introduce more refined technologies. Therefore, this is creating a positive hormonal contraceptive market outlook.

Policy initiatives and funding for family planning

Policies, such as supportive government policies and increased funding for family planning programs, facilitate the hormonal contraceptive market growth. Several governments in various regions, particularly in developing countries, have passed policies to ensure that individuals have access to contraceptives as part of public health and women's empowerment measures. These policies lower the cost of contraceptives, make reproductive health services comprehensive and available to everyone, and incorporate contraceptive education in public health campaigns. Furthermore, global consortia and institutions offer funding to help underserved areas access reproductive health services. All these measures seek to reduce the cost and convince individuals to get contraceptives. Policies that guarantee easy and low-priced access to hormonal contraceptives help to meet public health needs and other socio-economic targets.

Hormonal Contraceptive Market Segmentation:



IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, hormone, age group, and end user.

Breakup by Product:

Oral Contraceptive Pills Intrauterine Device (IUD) Injectable Birth Control Vaginal Rings Others

Oral contraceptive pills account for the majority of the hormonal contraceptive market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes oral contraceptive pills, intrauterine device (IUD), injectable birth control, vaginal rings, and others. According to the report, oral contraceptive pills represented the largest segment.

Oral contraceptive pills (OCPs) continue to lead the hormonal contraceptive market as the largest product segment due to their unmatched combination of efficacy, convenience, and availability. The hormonal contraceptive market overview suggests that pills are the most common contraceptive method worldwide due to their safety, which secures predictable and reliable family planning. In addition to their reliability, the market for these products is diversified by the variability of formulations, with pills available in combined and progestin-only versions that reflect medical and consumer preferences. Moreover, the market tendency is determined by the price of OCPs in comparison with other long-term hormone-conjugated contraceptives, and the ease of documentation based on the long history of using OCPs that, despite the side effects, remain safe. In confluence with this, the segment is still developing, and many new options have been and continue to be developed to reduce the side effects and enhance the safety and comfort of hormonal formulations. Overall, contraceptive OCPs remain the premise of reproductive health for women worldwide.



Breakup by Hormone:

Progestin-only Contraceptive

**Combined Hormonal Contraceptive** 

Combined hormonal contraceptive holds the largest share of the industry

A detailed breakup and analysis of the market based on the hormone have also been provided in the hormonal contraceptive market research report. This includes progestinonly contraceptive and combined hormonal contraceptive. According to the report, combined hormonal contraceptive accounted for the largest market share.

The hormone sub-segment is dominated by combined hormonal contraceptives (CHCs). The main factor contributing to the segment's high share is their very high contraceptive efficacy combined with significant health benefits. Among the beneficial effects, it is worth mentioning the guaranteed duration of the menstrual cycle and the severity of menstruation, the prevention of ovarian cysts, and the significant reduction in the risk of endometrial cancer. CHCs are available in the form of pills, vaginal rings, and patches, giving users an additional choice of the form of administration that is most convenient for them. Thus, CHCs are an attractive option for a wide range of users due to their great flexibility and additional health benefits. Among the concerns, some clinicians mention the risk of mood disorders and the likelihood of weight gain. However, ongoing improvements aim to decrease the risk of these side effects, enhancing user satisfaction and adherence.

Breakup by Age Group:

15-24 Years 25-34 Years 35-44 Years Above 44 Years



#### 15-24 years represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the age group. This includes 15-24 years, 25-34 years, 35-44 years, and above 44 years. According to the report, 15-24 years represented the largest segment.

The group of 15-24 years stands out as the largest segment of hormonal contraceptive users, based on identified trends in demographic distribution and social peculiarities. This age range usually refers to late adolescence and young adulthood, a period when individuals are most active in exploring and utilizing contraceptive options as part of their sexual and reproductive health management routines. In addition, the segment's considerable growth is driven by increased sexual activity among adolescents and young individuals, supported by broad educational programs that teach safe sex and promote the avoidance of unplanned pregnancies. Thus, this is also positively influencing the hormonal contraceptive market statistics. Educational institutions, healthcare providers, and community organizations pay special attention to this age group, conducting various outreach activities and consultations to make information about different methods of contraception more accessible. Similarly, the desire to build a career or complete education before starting a family also encourages these young individuals to seek adequate, secure, and reliable contraceptive options, contributing significantly to the strong representation of this submarket.

Breakup by End User:

Hospitals and Clinics

Homecare

**Ambulatory Surgical Centers** 

Others

Homecare exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, homecare, ambulatory surgical centers, and others. According to the report, homecare accounted for the largest market share.



The leading end-user in the hormonal contraceptive market is the homecare segment, driven by the convenience and privacy it offers. Given the current trend of consumers demanding to make their healthcare decisions from the comfort of their homes, the demand for products that can be self-administered was bound to increase. This trend is further facilitated by the fact that contraceptives have become more attainable than ever before. Oral pills, transdermal patches, and vaginal rings, for example, can now be utilized without anyone's help and are readily available on the market in most parts of the world. According to the hormonal contraceptive market analysis, many online platforms and telehealth services make access to these products easy, enhancing the appeal of managing contraceptive needs at home. Furthermore, the homecare trend corresponds to the overall developments in consumer-centered healthcare, whereby individuals are seeking optimal levels of convenience, confidentiality, and autonomy in attending to their health needs. These factors have significantly altered the dynamics within the hormonal contraceptive market.

Breakup by Region:

North America United States Canada Asia-Pacific China Japan Japan India South Korea Australia Indonesia Others



Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest hormonal contraceptive market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for hormonal contraceptive.

Geographically, North America is the leading market for hormonal contraceptives



globally due to the region's well-developed healthcare infrastructure, high awareness about contraceptive types, and strong government support. There are also several leading pharmaceutical companies in North America investing in the development of more convenient, effective, and safe contraceptives. At the same time, Americans are the most developed in terms of the culture of taking care of their health and they prefer to "swallow" an oral agent in advance rather than an intrauterine spiral. Additionally, many types of contraceptives are covered by insurance, including under policies, which enhance accessibility. Numerous educational programs provided by public and private organizations also inform about the benefits of using contraceptives. This comprehensive support ensures that North America is not only a large market but also a leading region in the global hormonal contraceptive space.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the hormonal contraceptive industry include:

Afaxys Inc.

Agile Therapeutics Inc.

Allergan Inc. (AbbVie Inc.)

Bayer AG

Cipla Limited

Johnson & Johnson

Merck & Co. Inc.

Pfizer Inc.

Piramal Group

Teva Pharmaceutical Industries Ltd.



(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major players in the hormonal contraceptive market are committed to funding research and enhancing the efficacy and safety of their products. They consistently reduce side effects and increase user convenience to gain market acceptance and keep quality leadership. Furthermore, firms including Bayer AG, Pfizer, and Merck & Co. want to extend their global footprint through acquisitions and alliances in developing countries, where the hormonal contraceptive demand is currently higher. Additionally, manufacturers frequently promote hormonal contraception and educate more women about the advantages associated. These developments support development goals while aiding more comprehensive public health policy goals.

Hormonal Contraceptive Market News:

April 25, 2024: Merck & Co. Inc. makes a statement of investing over ?300m (\$320.8m) to establish a new Life Science Research Center at its main office located in Darmstadt, Germany.

January 10, 2022: Agile Therapeutics, Inc. announced that it has entered into a new partnership with Afaxys Pharma, LLC to support the promotion of the Twirla® levonorgestrel and ethinyl estradiol transdermal system.

Key Questions Answered in This Report:

How has the global hormonal contraceptive market performed so far, and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global hormonal contraceptive market?

What is the impact of each driver, restraint, and opportunity on the global hormonal contraceptive market?

What are the key regional markets?

Which countries represent the most attractive hormonal contraceptive market?



What is the breakup of the market based on the product?

Which is the most attractive product in the hormonal contraceptive market?

What is the breakup of the market based on the hormone?

Which is the most attractive hormone in the hormonal contraceptive market?

What is the breakup of the market based on the age group?

Which is the most attractive age group in the hormonal contraceptive market?

What is the breakup of the market based on the end user?

Which is the most attractive end user in the hormonal contraceptive market?

What is the competitive structure of the market?

Who are the key players/companies in the global hormonal contraceptive market?



# Contents

#### **1 PREFACE**

## **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

#### **3 EXECUTIVE SUMMARY**

#### **4 INTRODUCTION**

- 4.1 Overview
- 4.2 Key Industry Trends

# **5 GLOBAL HORMONAL CONTRACEPTIVE MARKET**

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

# 6 MARKET BREAKUP BY PRODUCT

6.1 Oral Contraceptive Pills
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Intrauterine Device (IUD)
6.2.1 Market Trends
6.2.2 Market Forecast

6.3 Injectable Birth Control



6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Vaginal Rings
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast

## 7 MARKET BREAKUP BY HORMONE

- 7.1 Progestin-only Contraceptive7.1.1 Market Trends7.1.2 Market Forecast7.2 Combined Hormonal Contraceptive
  - 7.2.1 Market Trends
  - 7.2.2 Market Forecast

## 8 MARKET BREAKUP BY AGE GROUP

8.1 15-24 Years
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 25-34 Years
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 35-44 Years
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Above 44 Years
8.4.1 Market Trends
8.4.2 Market Forecast

# 9 MARKET BREAKUP BY END USER

- 9.1 Hospitals and Clinics9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Homecare



9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Ambulatory Surgical Centers
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

#### **10 MARKET BREAKUP BY REGION**

10.1 North America 10.1.1 United States 10.1.1.1 Market Trends 10.1.1.2 Market Forecast 10.1.2 Canada 10.1.2.1 Market Trends 10.1.2.2 Market Forecast 10.2 Asia-Pacific 10.2.1 China 10.2.1.1 Market Trends 10.2.1.2 Market Forecast 10.2.2 Japan 10.2.2.1 Market Trends 10.2.2.2 Market Forecast 10.2.3 India 10.2.3.1 Market Trends 10.2.3.2 Market Forecast 10.2.4 South Korea 10.2.4.1 Market Trends 10.2.4.2 Market Forecast 10.2.5 Australia 10.2.5.1 Market Trends 10.2.5.2 Market Forecast 10.2.6 Indonesia 10.2.6.1 Market Trends 10.2.6.2 Market Forecast 10.2.7 Others 10.2.7.1 Market Trends



10.2.7.2 Market Forecast 10.3 Europe 10.3.1 Germany 10.3.1.1 Market Trends 10.3.1.2 Market Forecast 10.3.2 France 10.3.2.1 Market Trends 10.3.2.2 Market Forecast 10.3.3 United Kingdom 10.3.3.1 Market Trends 10.3.3.2 Market Forecast 10.3.4 Italy 10.3.4.1 Market Trends 10.3.4.2 Market Forecast 10.3.5 Spain 10.3.5.1 Market Trends 10.3.5.2 Market Forecast 10.3.6 Russia 10.3.6.1 Market Trends 10.3.6.2 Market Forecast 10.3.7 Others 10.3.7.1 Market Trends 10.3.7.2 Market Forecast 10.4 Latin America 10.4.1 Brazil 10.4.1.1 Market Trends 10.4.1.2 Market Forecast 10.4.2 Mexico 10.4.2.1 Market Trends 10.4.2.2 Market Forecast 10.4.3 Others 10.4.3.1 Market Trends 10.4.3.2 Market Forecast 10.5 Middle East and Africa 10.5.1 Market Trends 10.5.2 Market Breakup by Country 10.5.3 Market Forecast

#### **11 SWOT ANALYSIS**



- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats

# **12 VALUE CHAIN ANALYSIS**

# **13 PORTERS FIVE FORCES ANALYSIS**

- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes

# **14 PRICE ANALYSIS**

# **15 COMPETITIVE LANDSCAPE**

15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Afaxys Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.2 Agile Therapeutics Inc. 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.3 Allergan Inc. (AbbVie Inc.) 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.4 Bayer AG 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.4.4 SWOT Analysis





15.3.5 Cipla Limited

- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Johnson & Johnson
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Merck & Co. Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Pfizer Inc.
  - 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Piramal Group
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 Teva Pharmaceutical Industries Ltd
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis



# **List Of Tables**

#### LIST OF TABLES

Table 1: Global: Hormonal Contraceptive Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Hormonal Contraceptive Market Forecast: Breakup by Product (in Million US\$), 2024-2032

Table 3: Global: Hormonal Contraceptive Market Forecast: Breakup by Hormone (in Million US\$), 2024-2032

Table 4: Global: Hormonal Contraceptive Market Forecast: Breakup by Age Group (in Million US\$), 2024-2032

Table 5: Global: Hormonal Contraceptive Market Forecast: Breakup by End User (in Million US\$), 2024-2032

Table 6: Global: Hormonal Contraceptive Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 7: Global: Hormonal Contraceptive Market: Competitive Structure

Table 8: Global: Hormonal Contraceptive Market: Key Players



# **List Of Figures**

#### LIST OF FIGURES

Figure 1: Global: Hormonal Contraceptive Market: Major Drivers and Challenges Figure 2: Global: Hormonal Contraceptive Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Hormonal Contraceptive Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 4: Global: Hormonal Contraceptive Market: Breakup by Product (in %), 2023 Figure 5: Global: Hormonal Contraceptive Market: Breakup by Hormone (in %), 2023 Figure 6: Global: Hormonal Contraceptive Market: Breakup by Age Group (in %), 2023 Figure 7: Global: Hormonal Contraceptive Market: Breakup by End User (in %), 2023 Figure 8: Global: Hormonal Contraceptive Market: Breakup by Region (in %), 2023 Figure 9: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 10: Global: Hormonal Contraceptive (Oral Contraceptive Pills) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 11: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 12: Global: Hormonal Contraceptive (Intrauterine Device-IUD) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 13: Global: Hormonal Contraceptive (Injectable Birth Control) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 14: Global: Hormonal Contraceptive (Injectable Birth Control) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 15: Global: Hormonal Contraceptive (Vaginal Rings) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 16: Global: Hormonal Contraceptive (Vaginal Rings) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 17: Global: Hormonal Contraceptive (Other Products) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 18: Global: Hormonal Contraceptive (Other Products) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 19: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 20: Global: Hormonal Contraceptive (Progestin-only Contraceptive) Market

Figure 21: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive)

Forecast: Sales Value (in Million US\$), 2024-2032



Market: Sales Value (in Million US\$), 2018 & 2023 Figure 22: Global: Hormonal Contraceptive (Combined Hormonal Contraceptive) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 23: Global: Hormonal Contraceptive (15-24 Years) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 24: Global: Hormonal Contraceptive (15-24 Years) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 25: Global: Hormonal Contraceptive (25-34 Years) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 26: Global: Hormonal Contraceptive (25-34 Years) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 27: Global: Hormonal Contraceptive (35-44 Years) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 28: Global: Hormonal Contraceptive (35-44 Years) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 29: Global: Hormonal Contraceptive (Above 44 Years) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 30: Global: Hormonal Contraceptive (Above 44 Years) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 31: Global: Hormonal Contraceptive (Hospitals and Clinics) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 32: Global: Hormonal Contraceptive (Hospitals and Clinics) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 33: Global: Hormonal Contraceptive (Homecare) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 34: Global: Hormonal Contraceptive (Homecare) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 35: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 36: Global: Hormonal Contraceptive (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 37: Global: Hormonal Contraceptive (Other End Users) Market: Sales Value (in Million US\$), 2018 & 2023 Figure 38: Global: Hormonal Contraceptive (Other End Users) Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 39: North America: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 40: North America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032



Figure 41: United States: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 42: United States: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 43: Canada: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 44: Canada: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 45: Asia-Pacific: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 46: Asia-Pacific: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 47: China: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 48: China: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 49: Japan: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 50: Japan: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 51: India: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 52: India: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 53: South Korea: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 54: South Korea: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 55: Australia: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 56: Australia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 57: Indonesia: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 58: Indonesia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 59: Others: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 60: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million



US\$), 2024-2032

Figure 61: Europe: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 62: Europe: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 63: Germany: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 64: Germany: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 65: France: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 66: France: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 67: United Kingdom: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 68: United Kingdom: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 69: Italy: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 70: Italy: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 71: Spain: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 72: Spain: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 73: Russia: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 74: Russia: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 75: Others: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 76: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 77: Latin America: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023 Figure 78: Latin America: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032 Figure 79: Brazil: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023



Figure 80: Brazil: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 81: Mexico: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 82: Mexico: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 83: Others: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 84: Others: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 85: Middle East and Africa: Hormonal Contraceptive Market: Sales Value (in Million US\$), 2018 & 2023

Figure 86: Middle East and Africa: Hormonal Contraceptive Market: Breakup by Country (in %), 2023

Figure 87: Middle East and Africa: Hormonal Contraceptive Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 88: Global: Hormonal Contraceptive Industry: SWOT Analysis

Figure 89: Global: Hormonal Contraceptive Industry: Value Chain Analysis

Figure 90: Global: Hormonal Contraceptive Industry: Porter's Five Forces Analysis



## I would like to order

Product name: Hormonal Contraceptive Market Report by Product (Oral Contraceptive Pills, Intrauterine Device (IUD), Injectable Birth Control, Vaginal Rings, and Others), Hormone (Progestinonly Contraceptive, Combined Hormonal Contraceptive), Age Group (15-24 Years, 25-34 Years, 35-44 Years, Above 44 Years), End User (Hospitals and Clinics, Homecare, Ambulatory Surgical Centers, and Others), and Region 2024-2032

Product link: https://marketpublishers.com/r/H86C88FCD84BEN.html

Price: US\$ 3,509.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/H86C88FCD84BEN.html</u>

# To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970